Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Adhesion-Mediated Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MPZL1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MPZL1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MPZL1 Products |
| Gene Delivery | MPZL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MPZL1 Products |
| Benchmark Ab | Anti-MPZL1 (Sequence of Clinical Reference Antibody) Recombinant positive control. |
View MPZL1 Products |
| Validator | MPZL1 siRNA Set For knockdown verification. |
View MPZL1 Products |
| Related Target A | PTPN11 (SHP-2) Direct intracellular signaling mediator of phosphorylated MPZL1 ITIM domains. |
View PTPN11 Products |
| Related Target B | CD147 (BSG) Synergistic cell-surface glycoprotein promoting tumor cell migration and matrix metalloproteinase expression. |
View CD147 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Epitope preservation of Ig-like V-type domain | HEK293 Expressed (Native Glycosylation) to ensure correct structural folding and mammalian post-translational modifications. |
| Subfamily counter screening (Avoiding myelin zero/MPZ cross-reactivity) | High-purity homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live MPZL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MPZL1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting MPZL1-mediated cell-adhesion resistance pathways in solid tumors, particularly in hepatocellular carcinoma (HCC) and triple-negative breast cancer (TNBC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Biotech Startups, Academic Consortia | HCC, Ovarian Cancer, TNBC | Internalization Assay (Need high-purity ECD-Fc for screening binders) |
| Monoclonal Antibody (Blocking/ADCC) | Oncology-focused Biopharma | Metastatic Solid Tumors | Cell-based Binding Assay (Need Lentivirus for Stable Cell Line generation) |
| Small Molecule (Inhibiting SHP-2 recruitment) | Global Pharmaceutical Entities | Drug-Resistant Solid Tumors | Protein-Protein Interaction (PPI) Assay (Need sequence-verified MPZL1 intracellular domain) |